51st week of 2015 patent applcation highlights part 7 |
Patent application number | Title | Published |
20150359766 | METHODS OF TREATING AUTISM WITH mGluR5 ANTAGONISTS - mGluR5 antagonists are used for the treatment of autism. The human treated by the methods of the invention can also have fragile X syndrome, epilepsy and anxiety. | 2015-12-17 |
20150359767 | COMPOSITION AND METHOD FOR COMPOUNDED THERAPY - A compounded transdermal cream for topical administration of a compounded therapy includes a nerve depressant such as gabapentin in an amount between approximately 5% and 15% by weight of the transdermal cream, an NSAID (Non-Steroidal Anti-Inflammatory Drug) such as nabumetone in an amount between approximately 5% and approximately 25% by weight of the transdermal cream, a tricyclic antidepressant such as amitriptyline in an amount between approximately 0.5% and approximately 4% by weight of the transdermal cream, a local anesthetic such as lidocaine and prilocaine in an amount between approximately 1% and approximately 7% by weight of the transdermal cream, and dimethyl sulfoxide (DMSO). | 2015-12-17 |
20150359768 | COMPOSITION AND METHOD FOR COMPOUNDED THERAPY - A compounded transdermal cream for the topical administration of a compounded therapy includes a first active agent selected from the group consisting of nabumetone in an amount between approximately 5.0% and approximately 25% by weight of the transdermal cream and amitriptyline in an amount between approximately 0.5% and approximately 4.0% by weight of the transdermal cream; a second active agent comprising a nerve depressant in an amount between approximately 5.0% and 15.0% by weight of the transdermal cream, wherein the nerve depressant is gabapentin; a third active agent comprising a local anesthetic in an amount between approximately 1.0% and approximately 7.0% by weight of the transdermal cream, wherein the local anesthetic comprises lidocaine and prilocaine; and dimethyl sulfoxide (DMSO). | 2015-12-17 |
20150359769 | METHOD FOR DECREASING SKELETAL MUSCLE DAMAGE AND/OR OXIDATIVE STRESS IN MAMMALS - A method for reducing muscle damage and/or oxidative stress in active mammals as disclosed. In one embodiment, the mammals are administered a carnitine supplement. The L-carnitine supplement may be administered without any other pharmaceutical or drug products. After physical activity the L-carnitine supplement can lower myoglobin, TBARS, and creatine kinase in the bloodstream. | 2015-12-17 |
20150359770 | AMINO ACID IMPROVING SENSITIVITY OF BATCTERIA TO SERUM - Glycine, threonine, and serine can enhance the sensitivity of bacteria to serum, plasma, or whole blood, and therefore can be used as molecules to improve the bactericidal effect of the serum, the plasma, or the whole blood. | 2015-12-17 |
20150359771 | TREATING PULMONARY CONDITIONS - Compositions, methods, and kits useful for treating pulmonary conditions are provided herein. Such compositions can contain synergizing amounts of a non-specific phosphodiesterase inhibitor, such as a methylxanthine, in combination with leucine and/or a leucine metabolite, and resveratrol. | 2015-12-17 |
20150359772 | DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE - Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction. | 2015-12-17 |
20150359773 | COMBINATION METHODS AND COMPOSITIONS INCLUDING SLEEP THERAPEUTICS FOR TREATING MOOD - Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments (he pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and non-pharmacological sleep therapies, and may include other ingredients such as antidepressants. The present invention relates pharmaceutical combinations and methods for their use to treat depression. | 2015-12-17 |
20150359774 | ACTIVE FRACTION OF A POLAR SOLVENT EXTRACT FROM THE LATEX OF EUPHORBIACEAE PLANTS - The present invention generally refers to an active fraction of an extract of the latex of plants from the family Euphorbiaceae in a polar solvent, as well as of one or more compounds contained therein, as well as the use of said fraction and/or said compounds, particularly in the treatment of cancer. The invention also refers to compositions comprising said active fraction and/or said compounds, as well as their use for the treatment of diseases concerning cell proliferation/angiogenesis, particularly cancer. | 2015-12-17 |
20150359775 | METHODS OF REDUCING RLP-C - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2015-12-17 |
20150359777 | PREPARATION METHOD OF POLYMERIC MICELLAR NANOPARTICLES COMPOSITION CONTAINING A POORLY WATER-SOLUBLE DRUG - Provided is a method for preparing a poorly water-soluble drug-containing polymeric micellar nanoparticle composition, which includes: dissolving a poorly water-soluble drug, a salt of polylactic acid or polylactic acid derivative, whose carboxylic acid end is bound to an alkali metal ion, and an amphiphilic block copolymer into an organic solvent; and adding an aqueous solution to the resultant mixture in the organic solvent to form micelles, wherein the method requires no separate operation to remove the organic solvent prior to the formation of micelles. The method for preparing a poorly water-soluble drug-containing polymeric micellar nanoparticle composition is simple, reduces the processing time, and is amenable to mass production. | 2015-12-17 |
20150359778 | Treatment of Triple Receptor Negative Breast Cancer - The present invention relates to the use of a liposomal preparation for the manufacture of a pharmaceutical composition and the use of such a composition for the treatment of “triple receptor negative” breast cancer. | 2015-12-17 |
20150359779 | COMPOSITION AND METHOD FOR TREATING DRY EYE SYNDROME - The present invention provides for compositions, medicaments, and methods for treating or alleviating the symptoms of dry eye syndrome or chronic dry eye. More specifically, the present embodiments provide for medicaments consisting of tocopherol or tocotrienol eyedrops. A single topical administration of tocopherol or tocotrienol eyedrops in the eyes of a subject suffering from dry eye alleviates symptoms for at least one day. In particular, the eyedrop medicament consists of α-tocopheryl acetate; α-tocopheryl acetate and about 0.5% aqueous component; or α-tocopheryl acetate, about 2.5% tocopherol emulsifier, and about 20% to about 30% aqueous excipient. | 2015-12-17 |
20150359780 | Compositions for Improved Body Composition - A nutritional supplement is provided comprising alpha-lipoic acid and curcumin. The nutritional supplement may be used for reducing weight or reducing weight gain, for reducing fat or reducing fat gain, for reducing loss in lean mass or maintaining lean mass, or for reducing loss of appetite or for maintaining appetite. | 2015-12-17 |
20150359781 | STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES - The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient. | 2015-12-17 |
20150359782 | NITROXIDES FOR USE IN TREATING OR PREVENTING DIABETES AND OBESITY - Pharmaceutical compositions are provided that are useful in treating diabetes. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of genes related to diabetes. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of diabetes. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl). | 2015-12-17 |
20150359783 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THEREOF - The present disclosure relates to compositions and pharmaceutical formulations comprising at least one active pharmaceutical ingredient chosen from nitrocatechol derivatives of formula I as defined herein and salts, esters, hydrates, solvates and derivatives thereof and methods of making said compositions and pharmaceutical formulations. | 2015-12-17 |
20150359784 | THIO COMPOUNDS - A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: | 2015-12-17 |
20150359785 | TREATMENT OF INFLAMMATION USING ALPHA 7 RECEPTOR-BINDING AGONISTS - Methods of inhibiting release of a proinflammatory cytokine from a macrophage are provided. The methods comprise treating the macrophage with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from the macrophage, wherein the cholinergic agonist is selective for an α7 nicotinic receptor. Methods for inhibiting an inflammatory cytokine cascade in a patient are also provided. The methods comprise treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an α7 nicotinic receptor. Methods for determining whether a compound is a cholinergic agonist reactive with an α7 nicotinic receptor are also provided. The methods comprise determining whether the compound inhibits release of a proinflammatory cytokine from a mammalian cell. Additionally, methods for determining whether a compound is a cholinergic antagonist reactive with an α7 nicotinic receptor are provided. These methods comprise determining whether the compound reduces the ability of a cholinergic agonist to inhibit the release of a proinflammatory cytokine from a mammalian cell. Oligonucleotides or mimetics capable of inhibiting attenuation of lipopolysaccharide-induced TNF release from a mammalian macrophage upon exposure of the macrophage to a cholinergic agonist are also provided. The oligonucleotides or mimetics consist essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an α7 receptor. Additionally, methods of inhibiting attenuation of TNF release from a mammalian macrophage upon exposure of the macrophage to a cholinergic agonist are provided. These methods comprise treating the macrophage with the above-described oligonucleotide or mimetic. | 2015-12-17 |
20150359786 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF - Inhibitors of retroviral propagation, methods of treatment and prevention of retroviral infections using the inhibitors, and pharmaceutical compositions including the inhibitors, are disclosed. | 2015-12-17 |
20150359787 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF - To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS. | 2015-12-17 |
20150359788 | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNF THERAPY - This application provides for a method of treating a human patient afflicted with anti-TNFα refractory Crohn's disease, of treating a human patient afflicted with non-fibrostenotic Crohn's disease, and of treating a human patient whose Crohn's disease had not been surgically treated, the method comprising periodically administering to the patient an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the patient. This application also provides for a method of inducing or maintaining clinical remission in a human patient afflicted with Crohn's disease comprising periodically administering to the patient an amount of laquinimod effective to induce or maintain clinical remission in the patient, which amount of laquinimod is less than 0.5 mg/day. | 2015-12-17 |
20150359789 | METHODS FOR TREATING PRURITUS - The present invention relates to methods for treating pruritus with anti-pruritic compositions. | 2015-12-17 |
20150359790 | STABILITY OF HYDROMORPHONE HYDROCHLORIDE SOLUTIONS - The present invention relates generally to a sterile hydromorphone hydrochloride solution that is substantially free of buffer. | 2015-12-17 |
20150359791 | COMPOSITION FOR TREATMENT OF PATHOGENS THAT ARE RESISTANT TO TETRACYCLINES - The invention relates to compounds and pharmaceutical compositions useful in combination with tetracyclines in the treatment of bacterial infections caused by Gram-positive and Gram-negative pathogens, with particular efficacy in tetracycline resistant strains. These compounds specifically bind to TetR and therefore prevent the transcriptional activation of tet resistance genes. The compounds have a potentiating effect on the activity of members of the tetracycline family, in particular of tetracycline, minocycline, doxycycline and tigecycline, in the treatment of tetracycline susceptible, intermediate and tetracycline resistant pathogens. | 2015-12-17 |
20150359792 | PROTOCOLS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) - Although it is known that certain benzylpiperazine-aminopyridines or open chain forms thereof are effective in stimulating neural growth in in vitro tests, it has now been surprisingly found that administering these compounds in a dosage range of 10 mg/day-130 mg/day over 25-35 days is effective in treating Major Depressive Disorder (MDD) such that statistically significant results can be obtained with samples of only six subjects. | 2015-12-17 |
20150359793 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES - The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 2015-12-17 |
20150359794 | IMPAIRMENT OF THE LARGE RIBOSOMAL SUBUNIT PROTEIN RPL24 BY DEPLETION OR ACETYLATION - Provided herein are compositions of histone deacetylase (HDAC) inhibitors for the treatment of cancers overexpressing the large ribosomal subunit protein 24 (RPL24) in a subject in need thereof. Provided herein are methods for treating RPL24-overexpressing cancers in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC inhibitor. Also provided herein are methods for inhibiting the viability of an RPL24-overexpressing cancer cell with an HDAC inhibitor. Also provided herein are methods for assessing the efficacy of an HDAC inhibitor against a cancer. | 2015-12-17 |
20150359795 | HIGH DRUG LOAD PHARMACEUTICAL COMPOSITIONS WITH CONTROLLABLE RELEASE RATE AND PRODUCTION METHODS THEREOF - High drug load pharmaceutical compositions and production methods thereof are provided. The pharmaceutical composition includes at least one viscous active pharmaceutical ingredient or a pharmaceutically acceptable salts thereof. The at least one viscous active pharmaceutical ingredient accounts for at least 60% by weight of the total solid weight of the pharmaceutical composition. The saturated solution of the at least one viscous active pharmaceutical ingredient has a viscosity of at least 20 centipoises at 25° C. Alternatively, the aqueous solution of the at least one viscous active pharmaceutical ingredient with a concentration lower than 55 wt % has at least a viscosity of at least 10 centipoises at 25° C. | 2015-12-17 |
20150359796 | QUINAZOLINONE COMPOUNDS - The present invention relates to quinazolinone compounds, processes for their preparation and their use as pharmaceutical agents for the treatment of Parkinson's disease (PD). The quinazolinone compounds are of general formula I | 2015-12-17 |
20150359797 | METHOD FOR TREATING CANCER USING A COMBINATION OF CHK1 AND ATR INHIBITORS - The present invention relates to methods of treating cancer in a patient by administering a compound useful as an inhibitor of ATR protein kinase in combination with a compound useful as an inhibitor of Chk1 protein kinase. The aforementioned combination displays a surprising synergistic effect in treating cancer despite the targeted protein kinases being within the same biological pathway. Moreover, the present invention also relates to methods of treating cancer by administering a compound useful as an inhibitor of ATR protein kinase; administering a compound useful as an inhibitor of Chk1 protein kinase; as well as administering a DNA damaging agent to a patient. | 2015-12-17 |
20150359798 | PIPERAZINYL DERIVATIVE REDUCES HIGH-FAT DIET-INDUCED ACCUMULATION OF FAT IN THE LIVERS, THERAPEUTICALLY - A method for inhibiting a liver disease is provided. The method includes administering a pharmaceutical composition of one of a piperazine analogue and a piperazine analogue complex to a warm-blooded animal suffering from the liver disease. | 2015-12-17 |
20150359799 | METHODS OF TREATING, PREVENTING AND DIAGNOSING LEUKEMIA AND OTHER BLOOD DISEASES AND DISORDERS - The present invention relates to preventing and treating leukemia and diseases and disorders of the blood, by inhibiting canonical Wnt signaling in the osteoblasts. The inhibition is accomplished by blocking specific molecules and receptors in the pathway. The present invention also relates to a method of diagnosing leukemia and disorders of the blood, and methods and assay for drug screening and basic research. | 2015-12-17 |
20150359800 | MODIFIED RELEASE PREPARATIONS CONTAINING OXCARBAZEPINE AND DERIVATIVES THEREOF - Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility-and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed. | 2015-12-17 |
20150359801 | COMPOSITIONS AND METHODS FOR REDUCING BODY FAT - The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions. | 2015-12-17 |
20150359802 | PARENTERAL PHARMACEUTICAL FORM WHICH RELEASES AROMATSE INHIBITOR AND GESTAGENS, FOR THE TREATMENT OF ENDOMETRIOSIS - The present invention for the treatment of endometriosis relates to providing a parenteral dosage form (delivery system) for the controlled release of an aromatase inhibitor (AI) in a daily release rate that does not induce stimulation of the ovaries by negative feed-back of the pituitary-ovarian-axis (which would cause secretion of gonadotropins and stimulation of ovarian follicular growth) and a gestagen in a daily release rate below the ovulation inhibition dose that provides contraceptive efficacy based on local effects (e.g. reducing and thickening of the cervical mucus impairing sperm ascension, effects on the endometrium and on tubal motility impairing implantation and egg transport). | 2015-12-17 |
20150359803 | METHODS AND MATERIALS FOR REDUCING SUPRESSION OF IMMUNE FUNCTION - This document provides methods and materials involved in reducing suppression of immune function in mammals. For example, methods and materials for (a) identifying a mammal as having an elevated level of CD14 | 2015-12-17 |
20150359804 | EXTENDED-RELEASE DRUG DELIVERY COMPOSITIONS - An extended-release drug delivery composition and method of administering the same is provided. The composition comprises microspheres loaded with a biologically-active agent and suspended in a soluble polymer capable of forming a film upon injection onto a biological surface. | 2015-12-17 |
20150359805 | Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions - The present invention relates to compounds of formula (I): | 2015-12-17 |
20150359806 | METHOD FOR PRODUCING PHYTOSTEROL/PHYTOSTANOL PHOSPHOLIPID ESTERS - The present invention relates to a method of producing a phytosterol ester and/or a phytostanol ester comprising: a) admixing a phospholipid composition comprising at least between about 10% to about 70% plant phospholipid and at least about 5% water; a lipid acyltransferase; and a phytosterol and/or a phytostanol; and b) separating or isolating or purifying at least one phytosterol ester and/or phytostanol ester from said admixture. The present invention also relates to compositions comprising the phytosterol ester and/or phytostanol ester produced by this method, including foodstuffs and personal care product (cosmetic) compositions. | 2015-12-17 |
20150359807 | Dietary Supplement Containing Vitamin A, D3 and Vitamin K2 and Uses Thereof - A composition comprising vitamin A, vitamin D and vitamin K | 2015-12-17 |
20150359808 | COMPOSITIONS AND METHODS FOR REDUCING HEPATOTOXICITY ASSOCIATED WITH DRUG ADMINISTRATION - The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound. | 2015-12-17 |
20150359809 | Sweet Taste Receptor Antagonist Compositions - The present disclosure relates to compositions comprising gymnemic acid, together with a form of zinc to block the unpleasant bitter taste of gymnemic acid as well as to extend the sweet taste blocking properties of gymnemic acid, resulting in palatable compositions for delivery to the oral cavity to block sweet taste receptors located therein. The present disclosure also relates to methods of reducing sugar consumption and reducing calorie intake via administration of such compositions to a subject. | 2015-12-17 |
20150359810 | METHODS FOR TREATING EPSTEIN-BARR VIRUS (EBV) ASSOCIATED CANCERS USING ORAL FORMULATIONS OF 5-AZACYTIDINE - Provided herein are methods for treating subjects having an EBV-associated cancer, including a relapsed or refractory solid tumor and Burkitt's lymphoma, wherein the method comprises administering to the subject 5-azacytidine. In certain of the methods, 5-azacytidine is administered alone or in combination with one or more anti-cancer agents. In certain of the methods, 5-azacytidine is formulated in an oral dosage form and administered orally. | 2015-12-17 |
20150359811 | GLA Monotherapy for Use in Cancer Treatment - The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen. | 2015-12-17 |
20150359812 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DRY EYE - This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside. | 2015-12-17 |
20150359813 | EFFECTIVE TREATMENT OF ESOPHOGEAL ADENOCARCINOMA USING TRICIRIBINE AND RELATED COMPOUNDS - The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. | 2015-12-17 |
20150359814 | Pharmaceutical Combinations of Flurbiprofen, Glucosamin and Capsaicin - The present invention relates to a pharmaceutical combination of flurbiprofen or a pharmaceutically acceptable salt thereof, glucosamine or a pharmaceutically acceptable salt thereof and capsaicin or a pharmaceutically acceptable salt thereof. Particularly, the present invention relates to a pharmaceutical combination for use in the treatment of pain and inflammatory symptoms associated with joint and cartilage disorders, especially with osteoarthritis and rheumatoid arthritis. | 2015-12-17 |
20150359815 | PAK1 INHIBITION FOR TREATMENT OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES - Methods are disclosed for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) using inhibition of p21 protein (Cdc42/Rac)-activated kinase (PAK1). | 2015-12-17 |
20150359816 | STABLE COMPOSITIONS COMPRISING HEPARINOID, ACUTE-ACTING ANESTHETIC, AND BUFFER - Improved methods for preparing compositions including a heparinoid, an acute-acting anesthetic, and a buffer are described. These methods result in compositions in which the heparinoid and the acute-acting anesthetic are at least 90% stable for one year. Compositions prepared by these methods and having such improved stability properties are also described, as well as methods for use of these compositions for treating, ameliorating, or preventing lower urinary tract disorders such as interstitial cystitis. | 2015-12-17 |
20150359817 | METHOD OF TREATING INFLAMED, IRRITATED, AND SENSITIVE SKIN USING A POLYLMER SUSPENSION SYSTEM, METHOD FOR PREPARING THE SAME, AND PRODUCTS MADE THEREOF - One aspect of the present invention provides a use of polymer 2-(methacryloyloxy)ethyl-2-(trimethylammonio)ethyl phosphate-stearylmethacrylate copolymer suspension as a compound which is beneficial to inflamed, irritated and sensitive skin. According to an alternative further aspect of the present invention there is provided a method of preparing a fabric which is non-irritating to the skin, said method comprising: scouring a fabric; rinsing the scoured fabric; coating the fabric with a polymer suspension having dual hydrophilic and hydrophobic characteristics; and finally setting the coated fabric to the required dimensions using a heat drying process so that an original handfeel of the fabric is not affected by the coating. | 2015-12-17 |
20150359818 | METHOD FOR PRODUCING A GAS TRANSPORTING RHEOLOGICAL MEDIUM - A method for producing a gas transporting rheological medium, said method comprises: (a) hydrating and dispersing a thickening agent in a fluid medium; (b) adding a first gas for dissolution and/or adsorption the fluid medium using a minimum fluid system pressure of about 7 psig; (c) mechanically emulsifying dimethylpolysiloxane into the fluid medium; (d) adding a source of one or more +2 valence cations to the suspension for 10 crosslinking to form a gel; and (e) dispensing the gel into a container. | 2015-12-17 |
20150359819 | TOPICAL FORMULATION - The present invention provides a formulation for the topical application to an external portion of a human body which includes the active ingredient of potassium alum. The topical formulation is comprised of potassium alum in a predetermined weight or amount in conjunction with other ingredients to assist in the treatment | 2015-12-17 |
20150359820 | USE OF TUNGSTEN (VI) SALTS FOR THE TREATMENT OF FEMALE INFERTILITY IN NON-DIABETIC MAMMALS - The present invention comprises the use of a therapeutically effective amount of a tungsten (VI) salt with a pharmaceutically or veterinarily acceptable cationic group, or a solvate of said salt, for the preparation of a medicinal product for the treatment of female infertility in non-diabetic mammals. | 2015-12-17 |
20150359821 | Microporous Zirconium Silicate for the Treatment of Hyperkalemia - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred composition has at least 95% ZS-9. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. These compositions are also useful in the treatment of chronic kidney disease, coronary vascular disease, diabetes mellitus, and transplant rejection. | 2015-12-17 |
20150359822 | METHODS TO REBALANCE THE HYPOTHALAMIC-PITUITARY-GONADAL AXIS - A hypothalamic-pituitary-gonadal (HPG) axis of a patient in need thereof is rebalanced by administering a therapeutically effective amount of at least one donor cell. | 2015-12-17 |
20150359823 | MULTIPOTENT ADULT STEM CELLS AND METHODS FOR ISOLATION - The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells. | 2015-12-17 |
20150359824 | IMPROVED OMEGA-3 FOOD SUPPLEMENT BASED ON MARINE OIL - A food supplement omega 3 based on marine oils (extracted from fish, fish byproducts, mollusks, krill, algae, microalgae) to fight against hypercholesterolemia and lipoprotein disruption leading to atherosclerosis and so to cardiovascular diseases. Optimization of Lipid Prevention Score (LPS) of at least one food supplement omega 3 by adding either high or low LPS oil (vegetable and/or marine) according to the LPS of the omega 3 based marine oils. This action permits to make a well balanced fatty acid product that will have a better effect against the rising of bad cholesterol levels in the blood. This product can be prescribed as part of a preventive diet and/or curative treatment for cardiovascular diseases since such illnesses lead to the highest human mortality in the industrialized countries (about 180,000 deaths annually in France, which corresponds to 32% of total deaths). | 2015-12-17 |
20150359825 | TREATING COLORECTAL CANCER WITH A WHOLE, LEECH SALIVA EXTRACT - Methods are provided for isolating and using a whole-saliva leech extract. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° C.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech. The methods can include revitalizing the leech by warming it at a temperature ranging from about 5° C. to about 40° C. Stable, lyophilized, whole-saliva extracts of a leech are also provided, the extract having a stable activity when stored for use at a temperature below about −20° C., the extract maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treat liquid tumors, treat diabetes, treat a viral disease, treat a parasitic disease, treat an antibacterial disease, or serve as an anti-oxidant. | 2015-12-17 |
20150359826 | TREATING A MELANOMA WITH A WHOLE, LEECH SALIVA EXTRACT - Methods are also provided for isolating and using a whole-saliva leech extract in the treatment of a melanoma. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° C.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech. The methods can include revitalizing the leech by warming it at a temperature ranging from about 5° C. to about 40° C. Stable, lyophilized, whole-saliva extracts of a leech are also provided, the extract having a stable activity when stored for use at a temperature below about −20° C., the extract maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treat liquid tumors, treat diabetes, treat a viral disease, treat a parasitic disease, treat an antibacterial disease, or serve as an anti-oxidant. | 2015-12-17 |
20150359827 | BLUE-GREEN ALGAE EXTRACT MIXTURES AND METHODS OF USE - Disclosed herein are compositions including a mixture of an aqueous extract of | 2015-12-17 |
20150359828 | Treatment Methods - A method is provided for treating a seaweed extract having a target molecule and a pyrogenic agent. The method includes inactivating the pyrogenic agent and/or removing the pyrogenic agent. The method results in a reduction in pyrogenicity of the extract. The method is useful in the preparation of pharmaceutical compositions and biomaterials for which pyrogen removal is critical. | 2015-12-17 |
20150359829 | METHOD OF INHIBITING ANGIOGENESIS - A method of inhibiting angiogenesis by applying a kind of protein polysaccharide of a (1→6)-β-D-glucan obtained from a residue of extraction of crushed dried fruiting body of | 2015-12-17 |
20150359830 | Hair Loss Compositions and Methods of Making and Using Same - A composition for promoting hair growth comprises hinoki oil, red clover extract, and a peptide. The hinoki oil can comprise from about 0.01% to about 5% by weight of the composition, the red clover extract can comprise from about 1 ppmw to about 1,000 ppmw of the composition, and the peptide can comprise from about 0.01 ppmw to about 500 ppmw of the composition. | 2015-12-17 |
20150359831 | Process to improve feed efficiency and carcass characteristics of animals - This invention relates to a process to improve the feed efficiency and carcass characteristics of (1) animals that are not showing clinical signs of disease or other microbial challenge and (2) animals that are not expected to show clinical signs of disease or other microbial challenge (that is, within the next 1-2 weeks or less) because of known management practices, such as weaning of piglets. The process of this invention can be used to decrease the cost of animal diets, to improve performance of animals and to improve the percentage of carcass in animals. | 2015-12-17 |
20150359832 | Anti-neuroinflammatory and antioxidative effects of Pi infusion - implications for neurodegenerative diseases - This invention relates to the use | 2015-12-17 |
20150359833 | Treatment of Virus-Based Diseases of the Skin - A method for treatment of virus-based diseases of the skin, in particular, herpes simplex virus type-1 and herpes zoster, which comprises topically administering to the skin of a subject suffering from a virus-based disease of the skin a therapeutically amount of an aqueous, aqueous/alcohol, or natural plant oil extract of dandelion. | 2015-12-17 |
20150359834 | COMPOUNDS, EXTRACTS AND METHODS FROM CHINESE MEDICINAL HERB SOPHORA FLAVESCENS THAT INHIBIT AIRWAY CONTRACTION - The present invention relates to extracts of | 2015-12-17 |
20150359835 | COMPOSITION OF A MEDICAL DEVICE OR COSMETIC PRODUCT BASED ON GRAPEFRUIT SEED EXTRACT, LADY'S MANTLE LEAF EXTRACT, STEVIA EXTRACT, AND CURCUMIN - The present invention relates to a composition, especially in gel form, comprising at least one grapefruit seed extract, at least one lady's mantle leaf extract, at least one stevia extract, and at least curcumin. The invention also relates to said composition in the form of a medical device or of a cosmetic composition, and to the use thereof for the treatment of complaints of the buccal cavity. Moreover, the invention also pertains to the use of the composition for its analgesic activity. The invention also relates to the use of said composition for preserving the resident flora of the buccal cavity. | 2015-12-17 |
20150359836 | Treatment of IBD and IBS Using Both Probiotic Bacteria and Fermented Cereal as Treatment - The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effecter. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease. | 2015-12-17 |
20150359837 | pH-Sensitive Polymer-Drug Conjugates for Targeted Delivery of Therapeutics - Polymeric delivery systems for boronic acid-containing therapeutics, related compounds and methods of use, for a pH-sensitive chemoselective approach to delivery of such a therapeutic. | 2015-12-17 |
20150359838 | METHODS FOR PREVENTING OR TREATING MITOCHONDRIAL PERMEABILITY TRANSITION - The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 2015-12-17 |
20150359839 | METHODS FOR PREVENTING OR TREATING INSULIN RESISTANCE - The invention provides methods of preventing or treating insulin resistance in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 2015-12-17 |
20150359840 | Autophagy-Inducing Peptide Analogs - An autophagy-inducing compound comprises an autophagy-inducing peptide comprising Beclin 1 peptides immediately N- and C-terminally flanked by moieties R | 2015-12-17 |
20150359841 | METHODS AND COMPOSITIONS COMPRISING A C-TERMINAL BAX PEPTIDE - In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells. | 2015-12-17 |
20150359842 | PRO-ANGIOGENIC FRAGMENTS OF PROMININ-1 AND USES THEREOF - Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these peptide analogs and uses thereof. | 2015-12-17 |
20150359843 | P53 ACTIVATING PEPTIDES - The present invention is directed to p53 activating peptides. The present further describes methods for generating these peptides and the use of these peptides. | 2015-12-17 |
20150359844 | ANTIMICROBIAL BACTERIA STRAINS AND USES THEREOF - The present invention provides novel antimicrobial bacteria strains and uses thereof to prepare novel antimicrobial agents. Also provided are the novel antimicrobial agents. | 2015-12-17 |
20150359845 | TRANSCRIPTION FACTOR-BASED GENERATION OF PACEMAKER CELLS AND METHODS OF USING SAME - Several embodiments disclosed herein relate generally to methods and compositions for the generation of biological pacemakers. In some embodiments, the methods comprise contacting non-pacemaker cells with one or more transcription factors (in vivo or in vitro) and inducing pacemaker functionality in the cells. | 2015-12-17 |
20150359846 | THERAPEUTIC METHOD - The present invention relates generally to a method of modulating an inflammatory response in a mammal and to agents useful for same. More particularly, the present invention relates to a method of modulating an inflammatory response in a mammal by modulating the functional activity of activin and thereby modulating the pro-inflammatory mediator cascade. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by an aberrant, unwanted or otherwise inappropriate inflammatory response including, inter alia, sepsis and inflammation of the airway. The present invention is further directed to methods for identifying and/or designing agents capable of modulating activin mediated regulation of the inflammatory response. | 2015-12-17 |
20150359847 | METHOD AND COMPOSITION FOR CONFERRING NEUROPROTECTION - The present invention relates to compositions and methods for neuroprotection. In particular, provided herein are compositions (for example, mesenchymal stem cell secretory factors) for alleviating and/or protecting against neuronal and neural stem cell damage (for example, resulting from traumatic brain injury), and methods of use thereof. | 2015-12-17 |
20150359848 | Methods and Related Kits for Treating and Regenerating Tooth Pulp and Periapical Tissues in a Mammal - In one embodiment, a method of regenerating tooth pulp in a mammal is provided. The method comprises removing at least a portion the existing tooth pulp of a mammal and adding amelogenin protein to the existing tooth pulp of the mammal to regenerate tooth pulp in a mammal. In another embodiment, a method of treating necrotic tooth pulp of a mammal is provided. The method comprises providing at least one necrotic tooth pulp of a mammal with an amelogenin protein. In yet another embodiment, a kit for regenerating tooth pulp in a mammal is provided. The kit comprises an adequate amount of amelogenin protein for regenerating tooth pulp in a mammal and instructions for applying the amelogenin protein to at least one tooth pulp of the mammal. | 2015-12-17 |
20150359849 | METHODS OF INCREASING NEURONAL CONNECTIVITY AND/OR TREATING A NEURODEGENERATIVE CONDITION - The inventions provided herein relate to methods, and compositions for increasing neuronal connectivity, neuronal survival and/or axonal growth of a population of neural cells in vitro, ex vivo or in vivo. For in vivo applications, in some embodiments, the methods and compositions described herein can be used to treat cognitive, motor and/or sensory function impairment and/or neurodegeneration in a subject or particularly a human subject {e.g., a human subject who is diagnosed as having, or having a risk, for a neurodegenerative and/or neurological condition such as Alzheimer's disease). Methods for determining a risk for a neurodegenerative condition or disorder, e.g., Alzheimer's disease, in a subject {e.g., a human subject) are also provided herein. | 2015-12-17 |
20150359850 | ADMINISTRATION OF AN ANTI-ACTIVIN-A COMPOUND TO A SUBJECT - The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors. | 2015-12-17 |
20150359851 | METHODS OF TREATING VESTIBULAR SCHWANNOMA AND REDUCING HEARING OR NEURITE LOSS CAUSED BY VESTIBULAR SCHWANNOMA - Methods to reduce the proliferation of vestibular schwannoma (VS) cells and/or provide neuroprotection to reduce the risk of sensorineural hearing loss (SNHL), vestibular dysfunction and facial nerve paralysis in subjects with VS. The methods can include one or more of decreasing TNF-α activity or expression; decreasing NF-κB expression or activity; decreasing COX-2 expression or activity; administering FGF2; decreasing HGF expression or activity; or decreasing c-Met expression or activity. | 2015-12-17 |
20150359852 | METHODS AND COMPOSITIONS FOR BONE FORMATION - A method and system to induce bone growth by locally delivering bone morphogenetic proteins (BMPs) to the target location for a prolonged period without invasive procedures are disclosed. The new bone growth is induced by delivering cells producing BMPs from transduced viral vectors to the target cite. In various embodiments, the cells are encapsulated in hydrogel microspheres that are non-degradable or degradable by enzymes produced during the bone formation process. Various embodiments may be used to induce spinal fusion or repair critical bone defects. | 2015-12-17 |
20150359853 | IL-15R ALPHA FORMS, CELLS EXPRESSING IL-15R ALPHA FORMS, AND THERAPEUTIC USES OF IL-15R ALPHA AND IL-15/IL-15R ALPHA COMPLEXES - In one aspect, described herein are cyclical administration regimens for the administration of complexes comprising interleukin-15 (“IL-15”) covalently or noncovalently bound to IL-15 receptor alpha (“IL-15Ra”) to patients in order to enhance IL-15-mediated immune function. In one aspect, these cyclical administration regimens achieve plasma levels of IL-15 above basal levels while minimizing the toxicity associated with IL-15 administration. In a specific aspect, the cyclical administration regimens are useful in the prevention, treatment, and/or management of disorders in which enhancing IL-15-mediated function is beneficial, such as cancer, infectious diseases, immunodeficiencies and lymphopenia. Also described herein are purified soluble forms of IL-15Ra, cells that recombinantly express soluble forms of IL-15Ra, and compositions comprising complexes of IL-15 covalently or non-covalently bound to soluble forms of IL-15Ra. Further described herein are host cells that recombinantly express IL15-Ra derivatives comprising a mutation or deletion in the extracellular domain cleavage site, including IL-15Ra derivatives comprising the extracellular domain of IL-15Ra and a transmembrane domain of a heterologous molecule. In addition, described herein are methods for propagating, activating and/or differentiating IL-15 responsive cells, comprising co-culturing an IL-15 responsive cell(s) with a host cell(s) that recombinantly expresses IL-15Ra, and isolating the IL-15 responsive cell(s) from the host cell(s). The IL-15 responsive cells that are immune cells can be administered to prevent, treat and/or manage various disorders, including cancer, an infectious disease, an immunodeficiency and lymphopenia. Further, described herein are methods of enhancing IL-15-mediated immune function as well as methods for preventing, treating and/or managing disorders in which enhancing IL-15-mediated function is beneficial, such as cancer, in a subject, the methods comprising administering to the subject a host cell that recombinantly expresses an IL-15Ra described herein. | 2015-12-17 |
20150359854 | INSULIN RECEPTOR INDUCED ELASTIN PRODUCTION - Compositions and methods for modulating the deposition of elastin by administering compositions including insulin receptor agonists are described herein. | 2015-12-17 |
20150359855 | METHODS OF USING THROMBIN DERIVATIVES TO TREAT MEDULLOBLASTOMA - Provided herein are methods for using a thrombin peptide derivative to treat a medulloblastoma. In one embodiment, the method includes administering to a subject having a medulloblastoma an effective amount of a thrombin peptide derivative, and exposing cells of the medulloblastoma of the subject to a cancer treatment after administering the thrombin peptide derivative to the subject. An example of a cancer treatment is radiation therapy. In one embodiment, viability of cells of the medulloblastoma is decreased compared to viability of cells of the medulloblastoma before the administering and the exposing. The cells of the medulloblastoma having decreased viability can be cancer stem cells. In one embodiment, shrinkage of the medulloblastoma in the subject is increased compared to shrinkage of the medulloblastoma before the administering and the exposing. | 2015-12-17 |
20150359856 | MATRIX COMPOSED OF A NATURALLY-OCCURRING PROTEIN BACKBONE CROSS LINKED BY A SYNTHETIC POLYMER AND METHODS OF GENERATING AND USING SAME - A method of treating a disorder characterized by tissue damage is provided. The method comprising providing to a subject in need-thereof a composition which comprises a synthetic polymer attached to denatured fibrinogen or a therapeutic portion of the fibrinogen, the composition being formulated for releasing the therapeutic portion of the fibrinogen in a pharmacokinetically regulated manner, thereby treating the disorder characterized by tissue damage or malformation. | 2015-12-17 |
20150359857 | Aerosolized fibrin hemostat - ClotSpray is a sprayable fibrin-based hemostatic agent applied from an aerosol can. The agent is intended for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and treatment of burns. It can be applied topically to the wound from an aerosol can without need of preparation, unfreezing or interruption during the length of the surgical procedure. Its crosslinking technology generates an adhesive fibrin sealant required for hemostasis. The attachment properties of the gel as well as the instant formation of a fibrin gel ensures that a strong stable fibrin clot will control light to moderate bleeding from a wound. | 2015-12-17 |
20150359858 | COMPOSITIONS AND METHODS FOR TREATING PATHOLOGICAL CALCIFICATION AND OSSIFICATION - The present invention includes compositions and methods for treating disease and disorders associated with pathological calcification or pathological ossification by modulating the level or activity of NPP1 or a mutant thereof, or a mutant NPP4 modified to exhibit ATP hydrolase activity similar to the hydrolase activity of NPP1. | 2015-12-17 |
20150359859 | A METHOD OF VIRUS INACTIVATION IN COMPOSITION COMPRISING FACTOR VII - The present invention relates to a method for inactivating viruses in a composition comprising blood coagulation factor VII, and more particularly, to a method for inactivating viruses comprising adding a surfactant to a composition comprising blood coagulation factor VII or a derivative thereof and a method for preparing a virus-inactivated composition comprising blood coagulation factor VII or the derivative thereof. | 2015-12-17 |
20150359860 | METHOD OF TREATING FIBROSIS IN SKELETAL MUSCLE TISSUE - A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic agents. | 2015-12-17 |
20150359861 | ENOLASE 1 (ENO1) COMPOSITIONS AND USES THEREOF - The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle. | 2015-12-17 |
20150359862 | Compositions and Methods for Treating Complications Associated with Diabetes - Compositions and methods for inhibiting diabetes-related complications are provided. | 2015-12-17 |
20150359863 | VACCINE COMPRISING AN OIL IN WATER EMULSION - The present invention provides an immunogenic composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil in water emulsion, wherein said oil in water emulsion comprises 0.5-10 mg metabolisable oil, 0.5-11 mg tocol and 0.1-4 mg emulsifying agent, per human dose. | 2015-12-17 |
20150359864 | PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDES - This invention provides a method for preparing a formulation comprising one or more types of peptides with the use of the same solvent in a simple manner without the need for selecting an adequate solvent for each peptide in accordance with its solubility. The invention provides a pharmaceutical composition comprising one or more types of peptides as active ingredients, a basic amino acid, and/or a base, and a method for producing such composition. | 2015-12-17 |
20150359865 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR T-CELL-MEDIATED AUTOIMMUNE DISEASE - Disclosed are synthetic nanocarrier compositions, and related methods, comprising autoimmune antigens and immunosuppressants to reduce immune responses to autoimmune antigens. | 2015-12-17 |
20150359866 | TREATMENT OF CERVICAL AND RELATED NEOPLASIAS WITH TOPICAL IMMUNOMODULATORS - The present invention provides methods for treating cervical and related HPV-associated neoplasias in subjects who are HPV16 negative comprising administering to the patient an effective amount of an immunomodulator, such as a Toll-like receptor agonist to the site of the lesions two or more times over a period of weeks to achieve regression of the neoplasia in the patient. Methods comprising the use of the immunomodulator with additional biological agents are also provided. | 2015-12-17 |